Revolution Medicines outlines $1.6B–$1.7B 2026 operating expenses as RAS(ON) inhibitor trials expand
The Trade Desk outlines at least $678M Q1 revenue target as AI innovation and CTV momentum continue
Ibotta outlines Q1 2026 revenue guidance of $78M-$82M with LiveLift driving transformation
Lifestance outlines $1.615B–$1.655B 2026 revenue target while advancing AI, EHR initiatives and $100M buyback
Paramount Skydance outlines $30B revenue target and $3.8B adjusted EBIT outlook as UFC deal accelerates streaming momentum
Root outlines 2026 strategy to accelerate PIF growth and expand to all contiguous states by 2027
Sarepta outlines $1.2B–$1.4B 2026 revenue target as ELEVIDYS educational push ramps up
Business